Nutrien (NTR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, Nutrien (NTR) reported revenue of $6.01 billion, up 12.3% over the same period last year. EPS came in at $0.97, compared to $0.39 in the year-ago quarter.The reported revenue represents a surprise of +3.09% over the Zacks Consensus Estimate of $5.83 billion. With the consensus EPS estimate being $0.93, the EPS surprise was +4.3%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Nutrien performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Phosphate - Sales volumes - Total: 666.00 KTon versus 689.39 KTon estimated by five analysts on average.Nitrogen - Sales volumes - Total: 2,827.00 KTon versus the five-analyst average estimate of 2,492.60 KTon.Potash - Sales volumes - Total: 4,059.00 KTon compared to the 3,903.40 KTon average estimate based on five analysts.Nitrogen - Sales volumes - Urea and ESN: 687.00 KTon versus 664.43 KTon estimated by four analysts on average.Sales- Retail (Nutrient Ag Solutions)- Total: $3.43 billion compared to the $3.53 billion average estimate based on six analysts. The reported number represents a change of +4.8% year over year.Sales- Potash: $1.26 billion versus $1.05 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +22.3% change.Sales- Phosphate: $561 million versus $528.13 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +20.1% change.Sales- Nitrogen: $1.2 billion versus the five-analyst average estimate of $1.08 billion. The reported number represents a year-over-year change of +30.5%.Net Sales- Potash: $1.12 billion compared to the $940.55 million average estimate based on five analysts. The reported number represents a change of +26.9% year over year.Net Sales- Nitrogen: $1.06 billion compared to the $941.29 million average estimate based on five analysts. The reported number represents a change of +34.1% year over year.Net Sales- Phosphate: $495 million compared to the $484.19 million average estimate based on five analysts. The reported number represents a change of +20.2% year over year.Net Sales- Eliminations: $-375 million versus the five-analyst average estimate of $-343.21 million. The reported number represents a year-over-year change of +36.4%.View all Key Company Metrics for Nutrien here>>>Shares of Nutrien have returned -11.5% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nutrien Ltd. (NTR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks